Dynavax Technologies (NASDAQ:DVAX) Trading Down 7.8% – Should You Sell?

Dynavax Technologies Co. (NASDAQ:DVAX)’s share price traded down 7.8% during mid-day trading on Friday . The stock traded as low as $12.31 and last traded at $12.35. 577,515 shares changed hands during trading, a decline of 73% from the average session volume of 2,138,228 shares. The stock had previously closed at $13.39.

Analyst Ratings Changes

DVAX has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a research report on Friday, November 8th. The Goldman Sachs Group reduced their target price on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th.

Dynavax Technologies Trading Down 8.8 %

The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $1.61 billion, a PE ratio of 93.92 and a beta of 1.34. The business’s fifty day moving average is $11.39 and its 200-day moving average is $11.31.

Institutional Investors Weigh In On Dynavax Technologies

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in shares of Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,685 shares in the last quarter. US Bancorp DE lifted its holdings in Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP purchased a new position in Dynavax Technologies in the 3rd quarter valued at about $45,000. Nisa Investment Advisors LLC boosted its position in Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 1,679 shares during the last quarter. Finally, Centiva Capital LP purchased a new stake in shares of Dynavax Technologies during the third quarter worth about $119,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.